# Glyx Therapeutics

> Orphan tauopathy disease solutions

Business model and tags: Pharma & life sciences, Has in-house R&D

## About Glyx Therapeutics

Pioneering innovative treatments for neurodegenerative disorders, specifically tackling orphan tauopathies and Alzheimer's disease to address urgent, unmet medical needs for patients facing challenging conditions.

## Key facts

- **Industry**: Biotechnology Research
- **Company size**: 1–10 employees
- **Headquarters**: Amiens, Hauts-de-France, France
- **Founded**: 2025
- **Revenue**: €2.4M – €18.7M (Tamtam estimate)
- **Website**: [glyxtherapeutics.com](http://www.glyxtherapeutics.com/)
- **LinkedIn**: [linkedin.com/company/glyx-therapeutics](https://www.linkedin.com/company/glyx-therapeutics)

## Glyx Therapeutics at a glance

Glyx Therapeutics is a company in the Biotechnology Research industry, headquartered in Amiens, Hauts-de-France, France.

Glyx Therapeutics was founded in 2025.

Glyx Therapeutics has 1–10 employees.

Glyx Therapeutics's revenue is €2.4M – €18.7M (Tamtam estimate).

## Frequently asked questions about Glyx Therapeutics

### What is Glyx Therapeutics's revenue?

Tamtam estimates Glyx Therapeutics's annual revenue at €2.4M – €18.7M.

### How many employees does Glyx Therapeutics have?

Glyx Therapeutics has 1–10 employees.

### Where is Glyx Therapeutics headquartered?

Glyx Therapeutics is headquartered in Amiens, Hauts-de-France, France.

---

Company data compiled by Tamtam from public sources and Tamtam's own analysis. Figures marked as estimates are modelled, not reported.

Source: https://www.tamtam.ai/c/glyx-therapeutics